SARS-CoV-2 (COVID-19) en pacientes con algún grado de inmunosupresión

Ren, 2020, Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study, Chin Med J (Engl)., 133, 1015, 10.1097/CM9.0000000000000722 Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med., 382, 727, 10.1056/NEJMoa2001017 Beeching, 2020, Enfermedad de coronavirus 2019 (COVID-19) Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet., 395, 497, 10.1016/S0140-6736(20)30183-5 Wang, 2020, Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA., 323, 1061, 10.1001/jama.2020.1585 Johns Hopkins University. Coronavirus resource center. 2020. Disponible en: https://coronavirus.jhu.edu/map.html Organización Panamericana De La Salud/Organización Mundial de la Salud. Brote de enfermedad por el Coronavirus ??(COVID-19)? 2020. Disponible en: https://www.paho.org/es/temas/coronavirus/enfermedad-por-coronavirus-covid-19 Chen, 2020, Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World J Pediatr., 16, 240, 10.1007/s12519-020-00345-5 Woo, 2009, Coronavirus diversity, phylogeny and interspecies jumping, Exp Biol Med (Maywood)., 234, 1117, 10.3181/0903-MR-94 Ashour, 2020, Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks, Pathogens., 9, 186, 10.3390/pathogens9030186 Guo, 2020, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status, Mil Med Res., 7, 11 Singhal, 2020, A review of coronavirus disease-2019 (COVID-19), Indian J Pediatr., 87, 281, 10.1007/s12098-020-03263-6 Li, 2020, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med., 382, 1199, 10.1056/NEJMoa2001316 Zhang, 2020, Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes, Emerg Microbes Infect., 9, 386, 10.1080/22221751.2020.1729071 To, 2020, Consistent detection of 2019 novel coronavirus in saliva, Clin Infect Dis., 71, 841, 10.1093/cid/ciaa149 Zhang, 2020, Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study, Lancet Infect Dis., 20, 793, 10.1016/S1473-3099(20)30230-9 Chen, 2020, Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, Lancet., 395, 809, 10.1016/S0140-6736(20)30360-3 Zhang, 2020, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy., 75, 1730, 10.1111/all.14238 Guan, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med., 382, 1708, 10.1056/NEJMoa2002032 Murthy, 2020, Care for critically ill patients with COVID-19, JAMA., 323, 1499, 10.1001/jama.2020.3633 Guan, 2020, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J., 55, 2000547, 10.1183/13993003.00547-2020 Yang, 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis., 94, 91, 10.1016/j.ijid.2020.03.017 Wang, 2020, Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis, Aging (Albany NY)., 12, 6049, 10.18632/aging.103000 Zhao, 2020, The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis, J Med Virol., 10.1002/jmv.25889 Roncon, 2020, Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome, J Clin Virol., 127, 104354, 10.1016/j.jcv.2020.104354 Guo, 2020, Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab Res Rev., 10.1002/dmrr.3319 Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol., 5, 811, 10.1001/jamacardio.2020.1017 Li, 2020, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol., 109, 531, 10.1007/s00392-020-01626-9 Herman, 2020, Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19, Neurology., 95, 77, 10.1212/WNL.0000000000009673 Ryan, 2020, COVID 19 and the patient with obesity - the editors speak out, Obesity (Silver Spring)., 28, 847, 10.1002/oby.22808 Kutlu, 2020, Dermatological diseases presented before COVID-19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?, Dermatol Ther., 10.1111/dth.13509 Cheng, 2020, Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int., 97, 829, 10.1016/j.kint.2020.03.005 2020, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Vashist, 2020, In vitro diagnostic assays for COVID-19: recent advances and emerging trends, Diagnostics (Basel)., 10, 202, 10.3390/diagnostics10040202 Sanders, 2020, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA., 323, 1824 Colson, 2020, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents., 55, 105932, 10.1016/j.ijantimicag.2020.105932 Wilkinson, 2020, RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials, BMJ., 369, m1626, 10.1136/bmj.m1626 Mehra, 2020, RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet. Mehra, 2020, Retraction - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet., 395, 1820, 10.1016/S0140-6736(20)31324-6 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis., 71, 732, 10.1093/cid/ciaa237 Stockman, 2006, SARS: systematic review of treatment effects, PLoS Med., 3, e343, 10.1371/journal.pmed.0030343 Grein, 2020, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med., 382, 2327, 10.1056/NEJMoa2007016 Liang, 2020, A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir, Eur J Med Chem., 201, 112527, 10.1016/j.ejmech.2020.112527 Horby, 2020, Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report, medRxiv. Xia, 2020, Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion, Blood., 136, 755, 10.1182/blood.2020007079 Rojas, 2020, Convalescent plasma in Covid-19: possible mechanisms of action, Autoimmun Rev., 19, 102554, 10.1016/j.autrev.2020.102554 Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA., 323, 1582, 10.1001/jama.2020.4783 Stockman, 2007, Severe acute respiratory syndrome in children, Pediatr Infect Dis J., 26, 68, 10.1097/01.inf.0000247136.28950.41 D’Antiga, 2020, Coronaviruses and immunosuppressed patients: the facts during the third epidemic, Liver Transpl., 26, 832, 10.1002/lt.25756 Hui, 2018, Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission, Lancet Infect Dis., 18, e217, 10.1016/S1473-3099(18)30127-0 2020, Comunicar los riesgos para la salud de COVID-19: una acción clave para ayudar a la población a protegerse y a mitigar su propagación 2020, CDC Centers for Disease Control and Prevention - Coronavirus Disease 2019 (COVID-19), People who are at increased risk for severe illness Liang, 2020, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol., 21, 335, 10.1016/S1470-2045(20)30096-6 Desai, 2020, COVID-19 and cancer: lessons from a pooled meta-analysis, JCO Glob Oncol., 6, 557, 10.1200/GO.20.00097 Wang, 2020, Risk of COVID-19 for patients with cancer, Lancet Oncol., 21, e181, 10.1016/S1470-2045(20)30149-2 Yu, 2020, SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China, JAMA Oncol., 6, 1108, 10.1001/jamaoncol.2020.0980 Lambertini, 2020, Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective, ESMO Open., 5, e000759, 10.1136/esmoopen-2020-000759 Pino, 2020, Cancer center recommendations to mitigate COVID-19 impact in patients with cancer: low-resource settings version, JCO Glob Oncol., 6, 569, 10.1200/GO.20.00093 Romanelli, 2020, Crucial aspects of the management of solid organ transplant patient with COVID-19: a narrative review, Preprints. Bösch, 2020, Attenuated early inflammatory response in solid organ recipients with COVID-19, Clin Transplant., 10.1111/ctr.14027 Guillen, 2020, Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation?, Am J Transplant., 20, 1875, 10.1111/ajt.15874 Gandolfini, 2020, COVID-19 in kidney transplant recipients, Am J Transplant., 20, 1941, 10.1111/ajt.15891 Qin, 2020, Perioperative presentation of COVID-19 disease in a liver transplant recipient, Hepatology., 10.1002/hep.31257 Li, 2020, Strategies for prevention and control of the 2019 novel coronavirus disease in the department of kidney transplantation, Transpl Int. Abbas, 2018 Wijnands, 2017, Infection-related health care utilization among people with and without multiple sclerosis, Mult Scler., 23, 1506, 10.1177/1352458516681198 Novi, 2020, COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?, Mult Scler Relat Disord., 42, 102120, 10.1016/j.msard.2020.102120 Louapre, 2020, Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis, JAMA Neurol., 10.1001/jamaneurol.2020.2581 Brownlee, 2020, Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic, Neurology., 94, 949, 10.1212/WNL.0000000000009507 Winkelmann, 2016, Disease-modifying therapies and infectious risks in multiple sclerosis, Nat Rev Neurol., 12, 217, 10.1038/nrneurol.2016.21 Ricardo, 2020, Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: a latin american survey, Mult Scler Relat Disord., 44, 102310, 10.1016/j.msard.2020.102310 Costa-Frossard, 2020, [EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic], Rev Neurol., 70, 329 Giovannoni, 2020, The COVID-19 pandemic and the use of MS disease-modifying therapies, Mult Scler Relat Disord., 39, 102073, 10.1016/j.msard.2020.102073 Fan, 2020, Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders, Neurol Neuroimmunol Neuroinflamm., 7, e787, 10.1212/NXI.0000000000000787 Anand, 2020, COVID-19 in patients with myasthenia gravis, Muscle Nerve., 62, 254, 10.1002/mus.26918 Delly, 2020, Myasthenic crisis in COVID-19, J Neurol Sci., 414, 116888, 10.1016/j.jns.2020.116888 Ramaswamy, 2020, COVID-19 in refractory myasthenia gravis - A case report of successful outcome, J Neuromuscul Dis., 7, 361, 10.3233/JND-200520 Jacob, 2020, Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic, J Neurol Sci., 412, 116803, 10.1016/j.jns.2020.116803 2020, Joint statement on the current epidemics of new Coronavirus 2020, COPID19 Worldwide survey of COVID-19 in PID patients 2020, Latest news on COVID 19 and PID 2020, Immune Deficiency Foundation 2020, COVID-19 and Immunodeficiency PID UK. COVID-19 – Wales - information and resources, Disponible en: http://www.piduk.org/whatarepids/management/covidwales 2020, COVID-19 and Primary Immunodeficiency: An IDF Virtual Education Event Pulvirenti, 2020, Health-related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID-19 pandemic, J Allergy Clin Immunol Pract., 8, 1894, 10.1016/j.jaip.2020.04.003 Blanco, 2020, COVID-19 in patients with HIV: clinical case series, Lancet HIV., 7, e314, 10.1016/S2352-3018(20)30111-9 Zhu, 2020, Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China, J Med Virol., 92, 529, 10.1002/jmv.25732 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med., 382, 1787, 10.1056/NEJMoa2001282 2020, Infecciones por Coronavirus. Diagnóstico y Tratamiento Del Amo, 2020, Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study, Ann Intern Med., 10.7326/M20-3689 Mascolo, 2020, Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better, J Med Virol., 10.1002/jmv.25881 Zheng, 2019, A lysosome-targetable near infrared fluorescent probe for glutathione sensing and live-cell imaging, Sens Actuators B Chem., 301, 127065, 10.1016/j.snb.2019.127065 Jiang, 2020, Maintaining HIV care during the COVID-19 pandemic, Lancet HIV., 7, e308, 10.1016/S2352-3018(20)30105-3 Lim, 2016, Biomarkers of immunosuppression, Clin Liver Dis., 8, 34, 10.1002/cld.570 Lversen, 2013, Immunosuppression for the non-transplant physician: what should you know?, Breathe., 9, 202, 10.1183/20724735.042112 Elens, 2020, Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions, Ther Drug Monit., 42, 360, 10.1097/FTD.0000000000000761 Lima, 2020, COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes, Transpl Infect Dis., 10.1111/tid.13382 Rodriguez-Cubillo, 2020, Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?, Am J Transplant., 10.1111/ajt.16141 Printz, 2020, When a global pandemic complicates cancer care: although oncologists and their patients are accustomed to fighting tough battles against a lethal disease, Coronavirus Disease 2019 (COVID-19) has posed an unprecedented challenge, Cancer., 126, 3171, 10.1002/cncr.33043 Meziyerh, 2020, Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics, Am J Transplant., 20, 1896, 10.1111/ajt.15943 Monti, 2020, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis., 79, 667, 10.1136/annrheumdis-2020-217424